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Background and Significance
• Cancer is the 2nd most common cause of death in the U.S.
• Up to 20% of all cancer patients develop brain metastases, which is 
associated with a poor prognosis
• Three different types of radiation therapy are frequently used to 
treat brain metastases:
• Whole brain radiation therapy (WBRT)
• Hippocampal avoidance whole brain radiation therapy (HA-WBRT)
• Stereotactic radiosurgery (SRS)
• WBRT is the standard treatment option – it is less costly than HA-
WBRT and SRS, but also causes more severe neurocognitive side 
effects (i.e., memory loss)
• For patients with multiple brain metastases, the best choice that 
balances recurrence risk, treatment-related toxicity, and financial 
cost remains unclear
• We conducted an economic evaluation of the cost-effectiveness of 
each of the three radiation treatment strategies, for patients with 
multiple (defined as 5-15) brain metastases
• The public health goals of the project included encouraging doctors 
to provide more patient-centered care, as well as addressing system-
wide issues around health equity and access to care by reducing 
overall healthcare costs
Methods
• We created a Markov model to simulate the disease course of a 
cohort of patients with 5-15 brain metastases receiving WBRT, HA-
WBRT, or SRS
• Disease states were defined as:
• Intracranial disease without neurocognitive deficit (NCD)
• Controlled intracranial disease without NCD
• Controlled intracranial disease with NCD
• Intracranial disease with NCD
• Death
• Key model parameters included:
• Treatment cost
• Utility values for each disease state
• Transition rates between the disease states 
• WBRT was set as the standard treatment option and incremental 
cost-effectiveness ratios (ICERs) were calculated for HA-WBRT and 
SRS to evaluate cost-effectiveness from a payer perspective
• Sensitivity analyses were performed to validate the robustness of the 
model
Markov Model
Patients begin in the “intracranial disease without NCD” state and receive
either WBRT, HA-WBRT, or SRS as an initial treatment strategy.
The model incorporates transition rates to simulate if/when patients: (1)
experience neurocognitive toxicity due to treatment; (2) recur and develop
new brain metastases; and (3) die due to their disease.
Results: Sensitivity Analysis
Discussion and Conclusions
• In the multiple metastasis setting, SRS is a cost-effective alternative 
to WBRT, whereas HA-WBRT does not meet the $100,000/QALY 
willingness-to-pay threshold
• The ICERs for SRS differ only slightly between the five, ten and 
fifteen metastasis patient cohorts, suggesting that SRS is a 
reasonable option for all patients with up to fifteen brain metastases
• The adoption of HA-WBRT for patients with brain metastases 
should be done selectively; consider reserving this treatment for 
patients with good performance status and relatively lengthy life 
expectancy
• These results may promote public health by helping oncologists 
make more cost-effective clinical decisions and provide more 
patient-centered care; it may also help decrease overall healthcare 
expenditures which will improve health equity and access to care
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Results: Base Case
The ICERs for SRS and
HA-WBRT (as compared
to standard WBRT) are





Strategy Incremental Cost  
(vs. WBRT) 
Incremental Effectiveness  
(vs. WBRT) 
ICER 
HA-WBRT (all cohorts) $3,650 0.022 $163,915 
SRS (5 metastasis cohort) $6,013 0.146 $41,198 
SRS (10 metastasis cohort) $7,010 0.146 $48,025 
SRS (15 metastasis cohort) $8,006 0.146 $54,852 
 
SRS is associated with both a high incremental cost and effectiveness as
compared to WBRT. In contrast, while HA-WBRT has a lower incremental
cost, the incremental effectiveness of HA-WBRT over WBRT is minimal.
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The Markov model and base case results were stable to probabilistic
sensitivity analyses that incorporated uncertainty in the model parameters
by adding a standard triangular distribution of ±10%.
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